当前位置: X-MOL 学术Eur. J. Clin. Microbiol. Infect. Dis. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays
European Journal of Clinical Microbiology & Infectious Diseases ( IF 3.7 ) Pub Date : 2021-01-06 , DOI: 10.1007/s10096-020-04128-8
Arantxa Valdivia 1 , Ignacio Torres 1 , Víctor Latorre 2 , Clara Francés-Gómez 2 , Eliseo Albert 1 , Roberto Gozalbo-Rovira 3 , María Jesús Alcaraz 1 , Javier Buesa 1, 3 , Jesús Rodríguez-Díaz 3 , Ron Geller 2 , David Navarro 1, 3
Affiliation  

Whether antibody levels measured by commercially available enzyme or chemiluminescent immunoassays targeting the SARS-CoV-2 spike (S) protein can act as a proxy for serum neutralizing activity remains to be established for many of these assays. We evaluated the degree of correlation between neutralizing antibodies (NtAb) binding the SARS-CoV-2 spike (S) protein and SARS-CoV-2-S-IgG levels measured by four commercial immunoassays in sera drawn from hospitalized COVID-19 patients. Ninety sera from 51 hospitalized COVID-19 patients were tested by a pseudotyped virus neutralization assay, the LIAISON SARS-CoV-2 S1/S2 IgG, the Euroimmun SARS-CoV-2 IgG ELISA, the MAGLUMI 2019-nCoV IgG, and the COVID-19 ELISA IgG assays. Overall, the results obtained with the COVID-19 ELISA IgG test showed the highest agreement with the NtAb assay (κ, 0.85; 95% CI, 0.63–1). The most sensitive tests were the pseudotyped virus NtAb assay and the COVID-19 ELISA IgG assay (92.2% for both). Overall, the degree correlation between antibody titers resulting in 50% virus neutralization (NtAb50) in the pseudotyped virus assay and SARS-CoV-2 IgG levels was strong for the Euroimmun SARS-CoV-2 IgG ELISA (rho = 0.73) and moderate for the remaining assays (rho = 0.48 to 0.59). The kinetic profile of serum NtAb50 titers could not be reliably predicted by any of the SARS-CoV-2 IgG immunoassays. The suitability of SARS-CoV-2-S-IgG commercial immunoassays for inferring neutralizing activity of sera from hospitalized COVID-19 patients varies widely across tests and is influenced by the time of sera collection after the onset of symptoms.



中文翻译:

通过使用商业酶和化学发光免疫测定法推断住院 COVID-19 患者血清中的 SARS-CoV-2 刺突结合中和抗体滴度

对于许多这些检测方法,通过商业上可用的酶或化学发光免疫测定法测量的针对 SARS-CoV-2 刺突 (S) 蛋白的抗体水平是否可以作为血清中和活性的代表仍有待确定。我们评估了结合 SARS-CoV-2 刺突 (S) 蛋白的中和抗体 (NtAb) 与 SARS-CoV-2-S-IgG 水平之间的相关程度,这些水平是通过四种商业免疫测定法对来自住院 COVID-19 患者的血清进行测量的。来自 51 名住院 COVID-19 患者的 90 份血清通过假型病毒中和试验、LIAISON SARS-CoV-2 S1/S2 IgG、Euroimmun SARS-CoV-2 IgG ELISA、MAGLUMI 2019-nCoV IgG 和 COVID -19 ELISA IgG 检测。总体而言,通过 COVID-19 ELISA IgG 测试获得的结果与 NtAb 检测的一致性最高(κ , 0.85; 95% CI,0.63–1)。最敏感的检测是假型病毒 NtAb 检测和 COVID-19 ELISA IgG 检测(两者均为 92.2%)。总体而言,Euroimmun SARS-CoV-2 IgG ELISA (rho = 0.73) 和中度相关性在假型病毒测定中导致 50% 病毒中和 (NtAb 50 ) 的抗体滴度与 SARS-CoV-2 IgG 水平之间的相关程度很强对于其余的测定(rho = 0.48 至 0.59)。血清 NtAb 50的动力学特征任何 SARS-CoV-2 IgG 免疫测定都无法可靠地预测滴度。SARS-CoV-2-S-IgG 商业免疫测定法用于推断住院 COVID-19 患者血清的中和活性的适用性在不同测试中差异很大,并受症状出现后血清采集时间的影响。

更新日期:2021-01-06
down
wechat
bug